Details
Stereochemistry | ACHIRAL |
Molecular Formula | I.Na |
Molecular Weight | 153.8959 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[131I-]
InChI
InChIKey=FVAUCKIRQBBSSJ-LAIFMVDKSA-M
InChI=1S/HI.Na/h1H;/q;+1/p-1/i1+4;
Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SODIUM IODIDE I 131 Approved UseSodium Iodide I 131 is indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodide. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodide. Launch Date1971 |
|||
Primary | SODIUM IODIDE I 131 Approved UseSodium Iodide I 131 is indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodide. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodide. Launch Date1971 |
Sample Use Guides
The recommended dosage for orally administered Sodium Iodide I 131 Capsule USP is based on the thyroid gland uptake as well as the size of the gland. Thyroidal uptake and size should be determined by the physician prior to treatment and may be useful in calculating the therapeutic dose to be administered to the individual patient. Recommended dosages of orally administered Sodium Iodide I-131 are: Disease therapy: Antihyperthyroid Therapy: Oral dose of 148 to 370 megabecquerels (4 to 10 millicuries). Toxic nodular goiters and other serious thyroid conditions may require larger dosages. Antineoplastic – Ablation of normal thyroid tissue: Initial oral dose of 1.1 to 3.7 gigabecquerels (30 to 100 millicuries).Subsequent ablation of metastases with oral dose of 3.7 to 7.4 gigabecquerels (100 to 200 millicuries).
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175872
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
||
|
WHO-VATC |
QV10XA01
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
||
|
NCI_THESAURUS |
C2125
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
||
|
WHO-VATC |
QV09FX03
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
||
|
WHO-ATC |
V10XA01
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
||
|
WHO-ATC |
V09FX03
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5038
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
DB09293
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
Sodium Iodide I 131
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
C47725
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
m10035
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | Merck Index | ||
|
29VCO8ACHH
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
29VCO8ACHH
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
71368
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
7790-26-3
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
DTXSID701014487
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
100000093019
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
SUB12294MIG
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
91535
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1644695
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
SUB127361
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
ALTERNATIVE | |||
|
7790-26-3
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY | |||
|
SUB127360
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
ALTERNATIVE | |||
|
279
Created by
admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD